B&L Pledges Commitment To Product Pipeline Despite R&D Cuts
This article was originally published in The Tan Sheet
Executive Summary
Bausch & Lomb remains dedicated to its R&D pipeline despite cutting its funding forecast for the remainder of the year, the company maintained during a third-quarter earnings call Oct. 19
You may also be interested in...
Pharma Firms Ready To Repatriate Billions Once “JOBS” Bill Is Signed
J&J intends to repatriate as much as $10 bil. held by foreign subsidiaries following President Bush's expected signing of the "JOBS" bill
Bausch & Lomb Looks To Vitamin Extension To Sustain Double-Digit Growth
Bausch & Lomb plans to launch a line extension and new formulation for its Ocuvite PreserVision vitamin brand this quarter
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC